FDA Authorizes Consumer Test that Reports Three Mutations in the BRCA Breast Cancer Genes

Test only reports 3 out of more than 1,000 known BRCA mutations and negative result doesn’t rule out increased cancer risk

Silver Spring, Maryland—(ENEWSPF)—March 6, 2018

By: Rosemary Piser

The Food and Drug Administration (FDA) has authorized the Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants). This is the first direct-to-consumer (DTC) test to report on three specific BRCA1/BRCA2 breast cancer gene mutations that are most common in people…